Form 4: 2seventy bio Director Wei Lin Reports Disposal of Shares and Stock Options Following Merger with Bristol-Myers Squibb

Director Wei Lin reports the disposal of common stock and stock options in 2seventy bio following the completion of a merger with Bristol-Myers Squibb, where shares were converted to cash at $5.00 per share.

Summary

• Wei Lin, a director of 2seventy bio, filed a Form 4 detailing changes in beneficial ownership following the merger of 2seventy bio with a subsidiary of Bristol-Myers Squibb Company.
• The merger was completed on May 13, 2025, with each share of 2seventy bio common stock being acquired for $5.00 in cash.
• As a result of the merger, Wei Lin disposed of 17,583 shares of common stock.
• Additionally, 15,267 shares underlying restricted stock units were cancelled and converted into the right to receive cash equal to the merger consideration.
• Stock options to purchase 24,100 shares of common stock with an exercise price of $3.93 were also cancelled and converted into the right to receive cash equal to the excess of the merger consideration over the exercise price.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports the completion of a merger and the resulting changes in ownership. It doesn't express positive or negative views, but rather provides factual information.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a trend of pharmaceutical companies acquiring biotechnology firms to expand their pipelines and capabilities, particularly in areas like cell and gene therapy, which is 2seventy bio's focus.

Comparison to Industry Standards

• Mergers and acquisitions are common in the biotech industry, with deal valuations varying based on pipeline assets, clinical stage, and market potential.
• Comparable acquisitions in the cell and gene therapy space often involve upfront payments plus contingent milestone payments based on clinical and regulatory success.
• The $5.00 per share valuation reflects the negotiated terms between 2seventy bio and Bristol-Myers Squibb, considering factors such as market conditions and the company's financial performance.

Stakeholder Impact

• Shareholders received $5.00 per share as part of the merger agreement.
• Employees' stock options and restricted stock units were treated as outlined in the merger agreement, with vesting acceleration and conversion to cash.
• The company is now a wholly owned subsidiary of Bristol-Myers Squibb, which may impact future operations and strategic direction.

Key Dates

Keywords

Form 4, Merger, 2seventy bio, Bristol-Myers Squibb, Wei Lin, Beneficial Ownership, Stock Options, Common Stock, Director